Valerio Therapeutics

ALVIO

Company Profile

  • Business description

    Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.

  • Contact

    49, Boulevard du General
    Martial Valin
    Paris75015
    FRA

    T: +33 145587600

    https://www.valeriotx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    38

Stocks News & Analysis

stocks

New ASX share on our best ideas list

This undervalued miner is unappreciated by the market.
stocks

Has the most hated company on the ASX 200 bounced back?

Encouraging results indicate a potential turnaround story.
stocks

Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown

We think Amazon stock looks attractive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,922.004.900.05%
CAC 407,628.7882.621.09%
DAX 4023,768.59342.621.46%
Dow JONES (US)44,028.43439.851.01%
FTSE 1009,107.3238.740.43%
HKSE24,733.45225.640.92%
NASDAQ20,988.02337.891.64%
Nikkei 22540,290.70508.90-1.25%
NZX 50 Index12,684.0445.36-0.36%
S&P 5006,311.6873.671.18%
S&P/ASX 2008,663.701.700.02%
SSE Composite Index3,583.3123.360.66%

Market Movers